The strong efficacy and manageable safety profile, combined with priority review, suggest a high likelihood of NMPA approval. Traders should monitor the NMPA decision timeline and any updates on global development plans. The ESMO GI presentation on July 4, 2026, may provide additional detail and investor attention.
Price Chart
Executive Summary
HUTCHMED announced positive pivotal Phase II results for fanregratinib in FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma (ICC), with an IRC-assessed ORR of 42.5% and median OS of 16.6 months. The NDA has been accepted and granted priority review by China's NMPA, positioning fanregratinib as a potential new treatment option in a targeted ICC population.
Key Facts
- Pivotal Phase II study met primary endpoint with IRC-assessed ORR of 42.5% (95% CI: 30.0%–53.6%) in advanced ICC patients with FGFR2 fusions/rearrangements.
- Median progression-free survival (PFS) was 6.9 months; median overall survival (OS) was 16.6 months.
- NDA for fanregratinib in this indication accepted and granted priority review by China's NMPA in December 2025.
- Drug-related Grade 3+ adverse events occurred in 48.3% of patients; treatment discontinuation due to AEs was only 2.2% with no treatment-related deaths.
- Fanregratinib is a novel, selective FGFR 1/2/3 inhibitor; HUTCHMED retains worldwide rights.
Financial Impact
Positive Phase II data and priority review status support potential approval in China, expanding HUTCHMED's oncology portfolio. Fanregratinib addresses a niche but high-unmet-need ICC population; peak sales potential not disclosed but could be material given orphan-like indication.
Risk Factors
- Competition from approved FGFR inhibitors (pemigatinib, infigratinib) in similar indications.
- Grade 3+ AE rate of 48.3% may raise safety concerns despite low discontinuation.
- Commercial success depends on pricing, reimbursement, and physician adoption in China.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3317235 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | 6-K | $14.11 $12.82 | ▼ −9.14% | ▼ −7.99% | $14.31 (+1.42%) |
Aug 31, 2026 4w ago | 6-K | $12.12 $13.88 | ▲ +14.52% | ▲ +14.66% | $14.31 (+18.07%) |
Aug 18, 2026 6w ago | 6-K | $12.64 $12.26 | ▼ −3.01% | ▼ −2.81% | $14.31 (+13.21%) |
Aug 17, 2026 6w ago | 6-K | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Aug 17, 2026 6w ago | Press Release | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Jul 30, 2026 9w ago | 6-K | $10.77 $11.83 | ▲ +9.84% | ▲ +6.22% | $14.31 (+32.87%) |
Jul 2, 2026 13w ago | 6-K | $11.44 $10.98 | ▼ −4.02% | ▼ −4.95% | $14.31 (+25.09%) |
Jun 30, 2026 13w ago | 6-K | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 30, 2026 13w ago | Press Release | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 29, 2026 13w ago | 6-K | $10.71 $11.65 | ▲ +8.78% | ▲ +7.39% | $14.31 (+33.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access